On this page you will find our recommendations sorted by BNF chapter.

Appraisal Reports are available to stakeholders on request.

Where a decision is >24 months old; these are highlighted in red. If you are a clinician working within the NTAG region and would like to prioritise an old decision for re-review please contact the professional secretary on nuth.nyrdtc.rxsupp@nhs.net

Title Documents Decision Date


Actipatch® for management of localised musculoskeletal pain Recommendation Not recommended 22/02/2022
Etanercept Biosimilar (Benepali®) Recommendation Recommended as a 1st line option 05/04/2016
Extracorporeal shockwave therapy for plantar fasciitis (NETAG) Recommendation Not recommended 10/07/2012
Infliximab biosimilars Recommendation Recommended as an option 02/06/2015


Infliximab Subcutaneous (Remsima®) Recommendation Recommended as an option during Covid-19 Pandemic. 22/02/2022
Orthotic functional electrical stimulation (FES) for drop foot of neurological origin (updated) Recommendation Recommended if patient fulfils specific criteria 08/09/2015
Rituximab (MabThera®) for severe rheumatoid arthritis (non-NICE indications) (NETAG) Recommendation Recommends rituximab in combination with methotrexate as first-line biological therapy in cases where there is an absolute contraindication to tumour necrosis factor inhibitor 11/10/2011
Rituximab Biosimilars Recommendation Approved for use as an option. 06/06/2017
Sequential use of TNF inhibitors for the treatment of Psoriatic Arthritis Recommendation Recommended as an option 08/09/2015